There are many places in which ML/AI methods can be of benefit to pharmaceutical research (several have already been covered on the show). David and Demissie explain where AI can fit in to in vivo studies, which carries it’s own benefits, but also with heightened risk to to human test subjects. They go on to cover several other areas of interest including AI for observation studies and real world evidence. It’s a “big tent” conversation as we lead up to the Pfizer/ASA/Columbia University Symposium on Risks and Opportunities of AI in Clinical Drug Development.

Mihaela van der Schaar will be following up in a subsequent episode on this subject.